The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ESMO 2019 | I-O in Gastric/GEJ cancer

Name: I-O in Gastric/GEJ cancer
Uploaded: 2019-09-28T00:00:00Z
Duration: 1 min 42 s
Description: Kohei Shitara, MD, National Cancer Center Hospital, Kashiwa, Japan, discussed his opinion on the future of immuno-oncology in gastric and gastroesophageal junction cancer at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

Kohei Shitara • 28 Sep 2019

ESMO 2019

Gastrointestinal Cancer Nivolumab Pembrolizumab

Kohei Shitara, MD, National Cancer Center Hospital, Kashiwa, Japan, discussed his opinion on the future of immuno-oncology in gastric and gastroesophageal junction cancer at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.